← ANALYST RATINGS · TIPRANKS
Vertex Pharmaceuticals (VRTX): analyst forecast and price target
Analyst consensus
Strong Buy16 Buy3 Hold0 Sell
Ratings of 19 analysts in the last 3 months · top analysts only12-month forecast
Based on 19 price targets given in the last 3 months, the average target is $580, the highest $665, the lowest $442. The average is +16.2% from the last price of $500.
Analyst ratings 37
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Mohit Bansal★★★★★★★★★★#754 · hits 60% · avg +10.9% | Wells Fargo | $550 | Buy | +10.1% | Reiterated | 15.10.26on TipRanks 07:30 | +1.8%next day −0.7% | ↗ |
| Tazeen Ahmad★★★★★★★★★★#1537 · hits 60% · avg +5.8% | Bank of America Securities | $667 | Buy | +33.5% | Reiterated | 15.10.26on TipRanks 06:45 | +1.8%next day −0.7% | ↗ |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $629 → $577−8.3% | Buy | +15.5% | Upgrade | 15.10.26on TipRanks Oct 14 23:05 | — | |
| Evan Seigerman★★★★★★★★★★#856 · hits 59% · avg +9.3% | BMO Capital | $600 | Buy | +20.1% | Reiterated | 12.10.26on TipRanks 09:15 | −0.5%next day −4.3% | ↗ |
| Tazeen Ahmad★★★★★★★★★★#1537 · hits 60% · avg +5.8% | Bank of America Securities | $672 → $667−0.7% | Buy | +33.5% | Reiterated | 12.10.26on TipRanks 06:50 | −0.5%next day −4.3% | ↗ |
| Geoff Meacham★★★★★★★★★★#407 · hits 60% · avg +15.3% | Citi | $575 → $585+1.7% | Buy | +17.1% | Reiterated | 12.10.26on TipRanks 06:15 | −0.5%next day −4.3% | ↗ |
| Brian Abrahams★★★★★★★★★★#481 · hits 57% · avg +15.1% | RBC Capital | $570 → $576+1.1% | Buy | +15.3% | Reiterated | 08.10.26on TipRanks 08:55 | 0.0%next day +0.8% · 5 days +1.4% | ↗ |
| Terence Flynn★★★★★★★★★★#815 · hits 60% · avg +10.8% | Morgan Stanley | $665 | Buy | +33.1% | Assigned | 07.10.26on TipRanks 08:15 | +0.9%next day 0.0% · 5 days −0.4% | ↗ |
| Tazeen Ahmad★★★★★★★★★★#1537 · hits 60% · avg +5.8% | Bank of America Securities | — | Buy | — | Reiterated | 29.09.26on TipRanks 11:09 | 0.0%next day −0.5% · 5 days −6.6% | ↗ |
| Michael Yee★★★★★★★★★★#3077 · hits 49% · avg +3.8% | UBS | $585 → $615+5.1% | Buy | +23.1% | Assigned | 28.09.26on TipRanks 09:35 | +1.0%next day 0.0% · 5 days −5.8% | ↗ |
| Jeffrey Walch★★★★★★★★★★#5662 · hits 100% · avg +19.5% | Bernstein | $608 | Buy | +21.7% | Reiterated | 25.09.26on TipRanks 07:15 | +0.2%next day +1.0% · 5 days −3.9% | ↗ |
| Akash Tewari★★★★★★★★★★#649 · hits 57% · avg +13.5% | Jefferies | $633 → $640+1.1% | Buy | +28.1% | Reiterated | 23.09.26on TipRanks Sep 25 07:15 | +1.0%next day +1.3% · 5 days +1.9% | ↗ |
| Danielle Brill★★★★★★★★★★#566 · hits 56% · avg +16.1% | Truist Financial | — | Buy | — | Reiterated | 23.09.26on TipRanks 07:55 | +1.0%next day +1.3% · 5 days +1.9% | ↗ |
| Louise Chen★★★★★★★★★★#1899 · hits 52% · avg +5.9% | Scotiabank | $558 | Buy | +11.7% | Reiterated | 23.09.26on TipRanks 07:35 | +1.0%next day +1.3% · 5 days +1.9% | ↗ |
| Evan Seigerman★★★★★★★★★★#856 · hits 59% · avg +9.3% | BMO Capital | $600 | Buy | +20.1% | Reiterated | 23.09.26on TipRanks 07:35 | +1.0%next day +1.3% · 5 days +1.9% | ↗ |
| Whitney Ijem★★★★★★★★★★#537 · hits 48% · avg +20.2% | Canaccord Genuity | $442 | Hold | −11.6% | Reiterated | 23.09.26on TipRanks 07:15 | +1.0%next day +1.3% · 5 days +1.9% | ↗ |
| Geoff Meacham★★★★★★★★★★#407 · hits 60% · avg +15.3% | Citi | $585 | Buy | +17.1% | Reiterated | 23.09.26on TipRanks 06:50 | +1.0%next day +1.3% · 5 days +1.9% | ↗ |
| Eliana Merle★★★★★★★★★★#4163 · hits 45% · avg +3.0% | Barclays | $617 | Buy | +23.5% | Reiterated | 23.09.26on TipRanks 05:05 | +1.0%next day +1.3% · 5 days +1.9% | ↗ |
| Salveen Richter★★★★★★★★★★#967 · hits 51% · avg +12.5% | Goldman Sachs | $653 | Buy | +30.7% | Reiterated | 22.09.26on TipRanks Sep 23 08:45 | +0.9%next day +1.0% · 5 days +3.5% | ↗ |
| Terence Flynn★★★★★★★★★★#815 · hits 60% · avg +10.8% | Morgan Stanley | $665 | Buy | +33.1% | Reiterated | 22.09.26on TipRanks Sep 23 06:14 | +0.9%next day +1.0% · 5 days +3.5% | ↗ |
| Paul Matteis★★★★★★★★★★#473 · hits 53% · avg +17.6% | Stifel Nicolaus | — | Hold | — | Reiterated | 22.09.26on TipRanks Sep 23 06:14 | +0.9%next day +1.0% · 5 days +3.5% | ↗ |
| Myles Minter★★★★★★★★★★#92 · hits 61% · avg +34.9% | William Blair | — | Buy | — | Reiterated | 22.09.26on TipRanks 14:15 | +0.9%next day +1.0% · 5 days +3.5% | ↗ |
| Andrew Fein★★★★★★★★★★#267 · hits 52% · avg +23.7% | H.C. Wainwright | $641 | Buy | +28.3% | Reiterated | 22.09.26on TipRanks 10:25 | +0.9%next day +1.0% · 5 days +3.5% | ↗ |
| Jessica Fye★★★★★★★★★★#1182 · hits 56% · avg +9.4% | J.P. Morgan | $515 → $560+8.7% | Buy | +12.1% | Initiated | 11.09.26on TipRanks 05:30 | −0.7%next day +1.2% · 5 days −1.3% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $628 | Buy | +25.7% | Reiterated | 09.09.26on TipRanks 00:06 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $629 | Buy | +25.9% | Reiterated | 09.09.26on TipRanks 00:06 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $614 | Buy | +22.9% | Reiterated | 09.09.26on TipRanks 00:06 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $598 | Hold | +19.7% | Reiterated | 09.09.26on TipRanks 00:06 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $628 | Buy | +25.7% | Reiterated | 09.09.26on TipRanks 00:06 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $555 → $629+13.3% | Buy | +25.9% | Upgrade | 20.08.26on TipRanks 00:06 | — | |
| Brian Abrahams★★★★★★★★★★#481 · hits 57% · avg +15.1% | RBC Capital | $570 | Buy | +14.1% | Reiterated | 12.08.26on TipRanks 07:05 | −1.0%next day −2.5% · 5 days +5.5% | ↗ |
| Naz Rahman★★★★★★★★★★#12198 · hits 36% · avg −7.5% | Maxim Group | $575 | Buy | +15.1% | Reiterated | 05.08.26on TipRanks 14:25 | +1.5%next day 0.0% · 5 days +8.1% | ↗ |
| Cory Kasimov★★★★★★★★★★#276 · hits 59% · avg +18.9% | Evercore ISI | $535 | Buy | +7.1% | Reiterated | 04.08.26on TipRanks 10:23 | −0.1%next day +1.5% · 5 days +10.7% | ↗ |
| Carter Gould★★★★★★★★★★#2194 · hits 53% · avg +6.3% | Cantor Fitzgerald | $590 → $595+0.8% | Buy | +19.1% | Reiterated | 04.08.26on TipRanks 07:56 | −0.1%next day +1.5% · 5 days +10.7% | ↗ |
| Mohit Bansal★★★★★★★★★★#754 · hits 60% · avg +10.9% | Wells Fargo | $540 → $550+1.9% | Buy | +10.1% | Assigned | 04.08.26on TipRanks 07:45 | −0.1%next day +1.5% · 5 days +10.7% | ↗ |
| Joseph Stringer★★★★★★★★★★#293 · hits 48% · avg +24.7% | Needham | — | Hold | — | Reiterated | 04.08.26on TipRanks 07:45 | −0.1%next day +1.5% · 5 days +10.7% | ↗ |
| Phil Nadeau★★★★★★★★★★#1350 · hits 48% · avg +8.7% | TD Cowen | $525 → $550+4.8% | Buy | +10.1% | Assigned | 04.08.26on TipRanks Aug 3 23:30 | −0.1%next day +1.5% · 5 days +10.7% | ↗ |
| Andy Chen★★★★★★★★★★#959 · hits 67% · avg +28.8% | Wolfe Research | $557 | Buy | +11.5% | Reiterated | 03.08.26on TipRanks Aug 4 11:05 | −2.8%next day −0.1% · 5 days +9.3% | ↗ |
| Brian Skorney★★★★★★★★★★#12116 · hits 37% · avg −5.6% | Robert W. Baird | $330 → $350+6.1% | Sell | −30.0% | Reiterated | 07.07.26on TipRanks 07:00 | −0.9%next day −4.3% · 5 days −9.3% | ↗ |
| Unknown Analyst | Raymond James | — | Hold | — | Reiterated | 24.06.26on TipRanks Jun 29 06:30 | +1.5%next day +0.9% · 5 days +3.1% | ↗ |
| Unknown Analyst | Guggenheim | $546 | Buy | +9.3% | Reiterated | 02.06.26on TipRanks 09:35 | −3.2%next day +1.5% · 5 days +7.8% | ↗ |
| Hans Engel★★★★★★★★★★#1835 · hits 58% · avg +11.1% | Erste Group | — | Hold | — | Reiterated | 05.05.26on TipRanks 07:00 | −2.1%next day −0.6% · 5 days +3.6% | ↗ |
| Nico Chen★★★★★★★★★★#2913 · hits 59% · avg +9.8% | DBS | $540 | Buy | +8.1% | Reiterated | 19.01.26on TipRanks Jan 22 04:25 | +2.2%next day +3.2% · 5 days +4.6% | ↗ |
| David Risinger★★★★★★★★★★#64 · hits 65% · avg +33.1% | Leerink Partners | $456 → $525+15.1% | Buy | +5.1% | Reiterated | 29.12.25on TipRanks 08:15 | −0.3%next day −1.2% · 5 days +1.3% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Vertex Pharmaceuticals
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $573 at a price of $523 (+9.7%); now: $589 at $500 (+18.0%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 32 | 24 | 36 | 42 | 50 | 37 |
| Hold | 11 | 8 | 8 | 8 | 9 | 6 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 02.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $4.76 (from $3.68 to $5.25). Last quarter: $4.73.
Sales
Next quarter’s sales estimate — $3.4B (from $3.3B to $3.5B). Last quarter: $3.3B.
Best top-analyst consensus in the sector · Healthcare
About Vertex Pharmaceuticals
- CEO: Reshma Kewalramani
- Employees: 6,400
- 50 Northern Avenue, Boston, MA, 02210, US
- www.vrtx.com
Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The company offers a range of approved medications for CF patients, including SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which target specific mutations within the cystic fibrosis transmembrane conductance regulator gene. Additionally, they provide TRIKAFTA for individuals with CF aged six years and older who possess at least one F508del mutation. Beyond its established CF therapies, Vertex maintains a robust and diverse clinical pipeline. This includes VX-864, currently in Phase 2 for alpha-1 antitrypsin (AAT) deficiency; VX-147, also in Phase 2, addressing APOL1-mediated focal segmental glomerulosclerosis (FSGS) and other serious kidney conditions; VX-880, a potential treatment for Type 1 Diabetes undergoing Phase 1/2 trials; VX-548, a NaV1.8 inhibitor in Phase 2 for various forms of acute, neuropathic, and musculoskeletal pain; and CTX001, which is in Phase 3 development for severe sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). The company distributes its pharmaceutical products through specialty pharmacies and distributors across the United States, while international sales are facilitated via a network of specialty distributors, retail chains, hospitals, and clinics. Vertex also engages in numerous strategic collaborations with partners such as Affinia Therapeutics, Arbor Biotechnologies, CRISPR Therapeutics, Kymera Therapeutics, Mammoth Biosciences, Moderna, Obsidian Therapeutics, Skyhawk Therapeutics, Ribometrix, Genomics plc, Merck KGaA, and X-Chem. Established in 1989, Vertex Pharmaceuticals is headquartered in Boston, Massachusetts.
Data from the stock’s TipRanks forecast page, read 29 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗